

# Autophagy Inhibition-Based ULK1 Lead Discovery for Dual Targeting of Cancer Cells and TME in Pancreatic Cancer Therapy

Cowell Biodigm Co., Ltd.



ONCOLOGY	Lead
Product Type	Small molecule
Indication	Pancreatic cancer and other solid tumors
Target	ULK1 (UNC-51-like kinase 1)
MoA(Mechanism of Action)	Inhibition of autophagy in cancer cell, cancer stem cell, and cancer-associated fibroblast
Competitiveness	DCC-3116 (under phase I/II development)
Development Stage	Lead
Route of Administration	PO or IV

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*